Government Healthcare Policy, Business and Technology

FDA grants emergency use authorization for Eli Lilly antibody treatment for COVID-19

Healthcare Finance: On Monday, the U.S. Food and Drug Administration granted Emergency Use Authorization for Eli Lilly and Company's investigational neutralizing antibody bamlanivimab. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of the antibody treatment, which is administered via a single intravenous infusion.

Read article